MLD10 in the Prevention of Migraine in Adults
A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of MLD10 in the Prevention of Migraine Headache in Adults
研究概览
详细说明
This is a multi-center, double-blind, randomized, placebo-controlled, parallel study of MLD10 for the prevention of migraine headache. The study population will consist of approximately 142 male and female subjects between 18 and 65 years of age with frequent episodic migraine as defined by International Classification of Headache Disorders-3beta criteria. Two MLD10 (243 mg (milligrams) of elemental magnesium) or placebo caplets will be taken twice daily for a total daily dose of 486 mg.
VISIT 1 - SCREENING
The following will be completed at Visit 1:
- Obtain written Informed Consent. The informed consent will be obtained in accordance with Good Clinical Practices (GCP) and all applicable regulatory requirements from each subject prior to participation in the study.
- Verify Inclusion/Exclusion Criteria. Subjects will meet all the inclusion and none of the exclusion criteria.
- Obtain demographics (race, ethnicity, sex, date of birth)
- Obtain medical, medication, and headache history. Data collected will include medical history and diagnoses, age at onset of migraine and other pertinent migraine/headache history, history of acute and prophylactic headache medications within the past 30 days, and history of other recent/concomitant medications.
- Obtain date of last menstrual cycle and perform urine pregnancy test, if appropriate. Results of the pregnancy test must be negative to continue in study.
- Perform physical and neurological examinations.
- Measure vital signs (height, weight, resting heart rate, and blood pressure).
- Review Baseline Headache Diary. Subjects will be instructed to complete a daily online headache diary. Assessments to be captured are start/stop time, severity, associated symptoms, use of rescue medications, and unusual symptoms.
- Administer Columbia-Suicide Severity Rating Scale (C-SSRS).
- Schedule Visit 2.
VISIT 2 - RANDOMIZATION
- Verify Inclusion/Exclusion Criteria. Subjects must continue to meet all inclusion (including ≥ 3 days of migraine during baseline) and none of the exclusion criteria.
- Perform urine pregnancy test, if appropriate. Results of the pregnancy test must be negative to continue in study.
- Measure vital signs (weight, resting heart rate, and blood pressure).
- Record any changes to concomitant medications.
- Record any Serious Adverse Events (SAE) since signing the Informed Consent.
- Review Baseline Headache Diary for completeness and continuing eligibility.
- Randomize subject
- Review Month 1 Headache Diary instructions (same instructions as those discussed for Baseline Headache Diary).
- Dispense Month 1 study medication. Subjects will be instructed how to take study medication, prohibited medications/foods, dosage limitations of study medication, and storage requirements. Subjects will be instructed to return all used/partially used/unused study medication at next office visit and medications reconciliation will be performed to ensure a compliance of at least 80%. Subjects not complying at an 80% level will be withdrawn, unless otherwise approved by the Sponsor and/or Clinvest. (Estimated to be < 10%)
- Administer C-SSRS.
- Administer MIDAS.
- Collect serum samples for electrolytes, creatinine, and ionized Mg.
- Schedule Visit 3.
VISIT 3 - END OF TREATMENT PERIOD MONTH 1
- Record any changes to concomitant medications.
- Record any Non-Serious Adverse Events (NSAE) and/or SAEs.
- Perform urine pregnancy test, if appropriate. Results of the pregnancy test must be negative to continue in study.
- Measure vital signs (weight, resting heart rate, and blood pressure).
- Review Month 1 Headache Diary for completeness.
- Review instructions for Month 2 Headache Diary (same instructions as those discussed for Month 1 Headache Diary).
- Collect Month 1 unused study medication and used packaging. Confirm 85% compliance of medication usage per study protocol.
- Dispense Month 2 study medication and review the dosage limitations of study medication, storage requirements, and to return all used/partially used/unused study medication at next office visit.
- Perform drug accountability.
- Administer C-SSRS.
- Collect serum samples for electrolytes, creatinine, and ionized Mg.
- Schedule Visit 4.
VISIT 4 - END OF TREATMENT PERIOD MONTH 2
- Record any changes to concomitant medications.
- Record any NSAEs/SAEs.
- Perform urine pregnancy test, if appropriate. Results of the pregnancy test must be negative to continue in study.
- Measure vital signs (weight, resting heart rate, and blood pressure).
- Review Month 2 Headache Diary for completeness.
- Review instructions for Month 3 Headache Diary (same instructions as those discussed for Month 2 Headache Diary).
- Collect Month 2 unused study medication and used packaging. Confirm 85% compliance for medication usage per study protocol.
- Dispense Month 3 study medication and review the dosage limitations of study medication, storage requirements, and to return all used/partially used/unused study medication at next office visit.
- Perform drug accountability.
- Administer C-SSRS.
- Collect serum samples for electrolytes, creatinine, and ionized Mg.
- Schedule Visit 5.
VISIT 5 - END OF TREATMENT PERIOD MONTH 3
- Record any changes to concomitant medications.
- Record any NSAEs/SAEs.
- Perform urine pregnancy test, if appropriate.
- Measure vital signs (weight, resting heart rate, and blood pressure)
- Perform physical/neurological examinations.
- Collect Month 4 unused study medication and used packaging.
- Perform drug accountability.
- Administer SGIC & complete PGIC.
- Administer MIDAS.
- Administer C-SSRS.
- Collect serum samples for electrolytes, creatinine, and ionized Mg.
- Exit subject.
研究类型
注册 (实际的)
阶段
- 阶段2
- 第三阶段
联系人和位置
学习地点
-
-
California
-
Carlsbad、California、美国、92011
- The Research Center of Southern California
-
San Francisco、California、美国、94109
- San Francisco Clinical Research Center
-
-
Florida
-
Oviedo、Florida、美国、32765
- Physician Associates of Florida Research Department
-
-
Georgia
-
Snellville、Georgia、美国、30039
- Dr. B. Abraham, P.C.
-
-
Michigan
-
Kalamazoo、Michigan、美国、49009
- Westside Family Medical Center, P.C.
-
-
Missouri
-
Saint Peters、Missouri、美国、63303
- StudyMetrix Research
-
Springfield、Missouri、美国、65807
- Clinvest Research, LLC
-
-
Tennessee
-
Memphis、Tennessee、美国、38020
- Baptist Memorial Hospital
-
Nashville、Tennessee、美国、37203
- Nashville Neuroscience Group
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- male or female, in otherwise good health, 18 to 65 years of age.
- history of frequent episodic migraine (3-14 migraine days per month) (with or without aura) according to the International Classification of Headache Disorders-3beta for at least 3 months.
- onset of migraine before age 50.
- stable history of migraine at least 3 months prior to screening.
- not currently taking a migraine preventive or has been taking preventive for at least 30 days prior to screening and agrees to not start, stop, or change medication and/or dosage during the study period.
if female of childbearing potential, has a negative urine pregnancy test at Visits 1-5 and uses, or agrees to use, for the duration of the study, a medically acceptable form of contraception as listed:
- complete abstinence from intercourse from 2 weeks prior to administration of study drug, throughout the study, and for 7 days after completion or premature discontinuation from the study; surgically sterile (hysterectomy or tubal ligation or otherwise incapable of pregnancy); sterilization of male partner when in a monogamous relationship; intrauterine device with published data showing lowest expected failure rate is less than 1% per year; double barrier method (i.e., 2 physical barriers OR 1 physical barrier plus spermicide) for a least 1 month prior to Visit 1 and throughout study; or hormonal contraceptives for at least 3 months prior to Visit 1 and throughout study.
- completion of online diary must be ≥ 80% compliance, unless otherwise approved by the Sponsor and/or Clinvest.
Exclusion Criteria:
- unable to understand the study requirements, the informed consent, or complete headache records as required per protocol.
- pregnant, actively trying to become pregnant, or breast-feeding.
- diagnosed with International Classification of Headache Disorders-3beta criteria for Chronic Migraine within 3 months prior to screening, at the time of screening, and/or during the baseline period.
- experienced the following migraine variants: basilar migraine, aura without headache, familial hemiplegic migraine, complicated migraine, ophthalmoplegic migraine and retinal migraine within the last year.
- history of medication overuse headache (MOH) (Appendix II) in the 3 months prior to study enrollment or during the baseline phase.
- history of medication overuse (MO) of ergotamines, triptans, opioids, analgesics, NSAIDS and combination therapies, as defined by ICHD-3beta criteria and/or MO during baseline period.
- history of substance abuse and/or dependence, in the opinion of the Investigator.
- history of impaired renal function that, in the investigator's opinion, contraindicates participation in this study.
- unstable neurological condition or a significantly abnormal neurological examination with focal signs or signs of increased intracranial pressure.
- suffers from a serious illness, or an unstable medical condition, one that could require hospitalization, or could increase the risk of adverse events.
has significant risk of suicide, defined as a "yes" answer to any of the following questions on the Columbia-Suicide Severity Rating Scale (C-SSRS), either at the screening visit (when assessing the prior 12 months) or at visit 2 (when assessing time since the screening visit):
- Questions 4 or 5 on the suicidal ideation section
- Any question on any item in the suicidal behavior section
- any psychiatric disorder with psychotic features, and/or any other psychiatric disorder not stable or well controlled, that would interfere in their ability to complete study activities.
- hypersensitivity, intolerance, or contraindication to the use of magnesium L-lactate dehydrate or any of its components.
- received any investigational agents within 30 days prior to Visit 1.
- plans to participate in another clinical study at any time during this study.
学习计划
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
有源比较器:MLD10
Subjects randomized to MLD10 will be dispensed a 28 day supply of magnesium L-lactate dehydrate for daily treatment.
A total of 120 caplets will be given each time at Visit 2, 3, and 4. Additional overage will be given to account for the 3 day window.
Subjects will be instructed to take two caplets of study medication BID (twice a day) at about the same time each day.
Subjects will be instructed regarding storage requirements and will be asked to return all used/partially used/unused medication containers at the next office visit.
|
其他名称:
|
安慰剂比较:Placebo
Subjects randomized to placebo will be dispensed a 28 day supply of matching placebo for daily treatment.
A total of 120 caplets will be given each time at Visit 2, 3, and 4. Additional overage will be given to account for the 3 day window.
Subjects will be instructed to take two caplets of study medication BID (twice a day) at about the same time each day.
Subjects will be instructed regarding storage requirements and will be asked to return all used/partially used/unused medication containers at the next office visit.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Migraine Headache Days
大体时间:Day 1(Screening) - Day 116 (Visit 5 End of Study)
|
Comparison of the mean change from baseline in the frequency of migraine headache days per 28-day period ending with the cessation of treatment period month 3 in subjects treated with MLD10 versus placebo. A migraine headache day will be defined as a calendar day (00:00 to 23:59) with 4 or more hours of migraine headache, fulfilling International Classification of Headache Disorders-3beta criteria, and/or any headache of any duration with the use of migraine-specific acute medications(s) (i.e. ergot alkaloids, ergot combinations, opioids, triptans, combination analgesics [simple analgesics combined with opioids or barbiturate with or without caffeine]). |
Day 1(Screening) - Day 116 (Visit 5 End of Study)
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Headache Days
大体时间:Day 1(Screening) - Day 116 (Visit 5 End of Study)
|
Comparison of the change from baseline of subjects treated with MLD10 versus placebo in the frequency of headache days during the 3 month treatment period. A headache day will be defined as any day not classified as a migraine day, but recorded headache of any severity and/or duration. |
Day 1(Screening) - Day 116 (Visit 5 End of Study)
|
Headache Duration
大体时间:Day 1(Screening) - Day 116 (Visit 5 End of Study)
|
Change from baseline (28 day period) in the total cumulative minutes of headache during each 28-day treatment period month 1, 2, & 3 in subjects treated with MLD10 versus placebo. All headaches and/or migraines will be including in this outcome analysis. |
Day 1(Screening) - Day 116 (Visit 5 End of Study)
|
Pain Severity
大体时间:Day 1(Screening) - Day 116 (Visit 5 End of Study)
|
Change from baseline (28 day period) in the average pain severity at time of onset compared to each 28-day treatment period month 1, 2, & 3 in subjects treated with MLD10 versus placebo.
Headache pain severity was measured on a scale 1 = Mild, 2 = Moderate, 3 = Severe.
|
Day 1(Screening) - Day 116 (Visit 5 End of Study)
|
Acute Medication Usage
大体时间:Day 1(Screening) - Day 116 (Visit 5 End of Study)
|
Change from baseline (28 day period) in the total number of acute headache pain medications used during each 28 day treatment period month 1, 2, & 3 in subjects treated with MLD10 versus placebo.
|
Day 1(Screening) - Day 116 (Visit 5 End of Study)
|
Migraine Disability Assessment Scale (MIDAS)
大体时间:Day 29 (Randomization) & Day 116 (Visit 5 End of Study)
|
Change from Visit 2 to Visit 5 in the total MIDAS score in subjects treated with MLD10 versus placebo. The MIDAS test determines how severely migraines affect daily functioning. The responses of a variety of questions will be scored according to the questionnaire's scoring guide. A total score will be calculated ranging from 0-93. A score of 0-5 indicates little or no disability, 6-10 mild disability, 11-20, moderate disability, 21+ severe disability. |
Day 29 (Randomization) & Day 116 (Visit 5 End of Study)
|
Subject Global Impression of Change (SGIC)
大体时间:Day 116 (Visit 5 End of Study)
|
Comparison of SGIC at Visit 5 in subjects treated with MLD10 versus placebo. Global impression of change rated by the subject will be assessed using a 7-point Likert scale ranging from -3 to 3 with -3 = very much worse, -2 = much worse, -1 = minimally worse, 0 = no change, 1 = minimally improved, 2 = much improved, 3 = very much improved. |
Day 116 (Visit 5 End of Study)
|
Physician Global Impression of Change (PGIC)
大体时间:Day 116 (Visit 5 End of Study)
|
Comparison of PGIC at Visit 5 in subjects treated with MLD10 versus placebo. The PGIC will be an impression of change rated by the investigator using a 7-point Likert scale ranging from -3 to 3 with -3 = very much worse, -2 = much worse, -1 = minimally worse, 0 = no change, 1 = minimally improved, 2 = much improved, 3 = very much improved. |
Day 116 (Visit 5 End of Study)
|
合作者和调查者
合作者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
安慰剂的临床试验
-
City of Hope Medical CenterNational Cancer Institute (NCI)主动,不招人造血和淋巴细胞肿瘤 | 骨髓纤维化 | 慢性淋巴细胞白血病 | 缓解期成人急性髓性白血病 | 骨髓增生异常综合症 | 缓解期成人急性淋巴细胞白血病 | 骨髓增殖性肿瘤 | 慢性期慢性粒细胞白血病,BCR-ABL1 阳性 | 成人淋巴母细胞淋巴瘤 | 加速期慢性粒细胞白血病,BCR-ABL1 阳性 | HLA-A*0201 阳性细胞存在 | 巨细胞病毒感染 | 成人霍奇金淋巴瘤 | 成人非霍奇金淋巴瘤美国
-
Mila (bMotion Technologies)完全的
-
Universidad Autonoma de MadridCentro Universitario La Salle完全的